Publicly traded biotechnology company, Regen Biopharma, Inc. has just announced it has filed a utility patent application with the US Patent and Trademark Office for its breakthrough immuno-oncology treatment, dCellVax. This therapeutic works by stimulating the body’s dendritic cells to help activite immune responses against cancer.
Regen’s application is based on the company’s experience in harnessing dendritic cells, along with previous publications authored by Dr. Wei-Ping Min, a Professor at the University of Western Ontario and member of the company’s scientific advisory board, and previously issued US Patent No. 8,389,708.
Regen Biopharma is determined to find groundbreaking methods to harness the body’s dendritic or “professional antigen presenting” cells to provide millions of cancer patients a less toxic and less debilitating treatment option, compared to traditional chemo- and radiotherapy.
“Our filed IND # 16200 for dCellVax leverages dendritic cells that are modified outside of the body to trigger an immune response against breast cancer. In the newly filed patent application we cover means of activating dendritic cells inside the body, with the hope of stimulating T cell responses to clear prostate cancer,” said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma. “Effectively treating cancer requires a multi-level attack; by leveraging ex vivo activated dendritic cells combined with means of activating dendritic cells in vivo, we anticipate synergistic tumor responses.”
“Regen BioPharma is excited about accumulation of intellectual property in its immuno-oncology program. By protecting the inventions of our scientists we aim to not only bring new products to the market, but also to position ourselves for potential licensing and co-development transactions,” said David Koos, President, CEO and Chairman of Regen BioPharma, Inc.
Researchers from Johns Hopkins University’s Kimmel Cancer Center and James Buchanan Brady Urological Institute have recently released data showing that men with advanced prostate cancer (PC) and detectable levels of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy equally as men who lack AR-V7. The study, entitled, “Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer,” was published in the latest edition of JAMA Oncology.